Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, EMT, and Antiviral Therapeutics Development
DEAD-box helicase 5 (DDX5, also known as p68) is an essential RNA helicase that plays pivotal roles in transcriptional regulation, pre-mRNA splicing, and ribosome biogenesis. In oncogenic contexts, phosphorylation of DDX5 at Tyr593 (yielding pDDX5) by upstream kinases such as c-Abl mediates epithelial-mesenchymal transition (EMT) and promotes nuclear translocation of beta-catenin. Targeting the pDDX5 axis is a compelling therapeutic strategy to disrupt Wnt/beta-catenin signaling and overcome drug resistance in solid tumors. Additionally, pDDX5 acts as a host factor for several viruses (e.g., HCV, SARS-CoV-2), opening an antiviral development angle.
TarMart Solution Ecosystem & Related Targets
To support discovery programs targeting the DDX5/pDDX5 signaling axis, TarMart offers a comprehensive suite of sequence-verified, high-purity reagents. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DDX5 Recombinant Protein (Wild-Type & Y593D Phosphomimetic). Purity >95% by SDS-PAGE. Sequence Verified. Theoretical MW confirmed by MS. Endotoxin controlled. | View DDX5 Products |
| Gene Delivery | DDX5 Promise-ORF / Lentivirus: Full-length ORF for stable cell line generation (WT, Y593F, Y593D mutants available). | View DDX5 Products |
| Benchmark Ab | Anti-pDDX5 (Tyr593) Recombinant Antibody: Recombinant positive control for Western Blot, IHC, and IP validation. | View DDX5 Products |
| Validator | DDX5 siRNA Set: Validated pool of 3 target-specific siRNAs for knockdown verification. | View DDX5 Products |
| Related Target A | ABL1 (c-Abl): The primary tyrosine kinase responsible for DDX5 Tyr593 phosphorylation. | View ABL1 Products |
| Related Target B | CTNNB1 (Beta-catenin): Downstream transcription factor partner that dimerizes with pDDX5 during EMT. | View CTNNB1 Products |
| Related Target C | DDX17: Highly homologous family member required for selectivity/counter-screening assays. | View DDX17 Products |
| Related Target D | ESR1 (ER-alpha): Co-activator in breast cancer pathways; pDDX5 modulates ER signaling. | View ESR1 Products |
| Related Target E | DDX3X: Homologous DEAD-box helicase used for off-target selectivity profiling. | View DDX3X Products |
Critical Assay Challenges and Technical Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mimicking active pDDX5 in vitro | Recombinant DDX5 Y593D (phosphomimetic mutant) available with >95% purity for binding assays. |
| DDX17 subfamily cross-reactivity | High-purity DDX17 recombinant protein panel available for counter-screening. |
| Lack of reliable positive controls | Sequence-defined recombinant anti-pDDX5 (Tyr593) benchmark antibodies. |
| Target specificity verification | Sequence-verified siRNA sets for robust target knockdown validation in cell-based assays. |
| Phospho-specificity validation | Strictly controlled phosphorylation-state mutants (Y593D, Y593F) with >95% purity. |
| Intracellular target accessibility | High-fidelity recombinant proteins for PROTAC and small molecule binding assays, plus lentivirus for stable cell-line construction. |
Live pDDX5 / DDX5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The development of DDX5/pDDX5-targeted therapeutics is expanding from academic validation into translational drug discovery. Due to its intracellular localization and the lack of a traditional druggable pocket, traditional monoclonal antibody approaches are ineffective. Instead, the global pipeline is shifting toward small-molecule allosteric inhibitors, PROTACs (Proteolysis Targeting Chimeras) for targeted protein degradation, peptide-based disruptors of the pDDX5-beta-catenin interaction, and RNA-based therapeutics. Targeting the phosphorylated state (pDDX5 Tyr593) specifically allows selective intervention in cancer cells undergoing EMT while sparing normal physiological DDX5 functions in healthy tissues. In addition, pDDX5's role as a host factor in viral replication (e.g., HCV, SARS-CoV-2) opens an antiviral development angle that is gaining interest from emerging startups.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic/Biotech Consortia | Colorectal Cancer, Breast Cancer | Selectivity assay (need DDX5 vs. DDX17 recombinant proteins). |
| PROTACs / Degraders | Targeted Degradation Pioneers, Academic/Preclinical | Castration-Resistant Prostate Cancer, Refractory Cancers | Degradation kinetics (need lentivirus for stable cell-line construction, native-fold antigens). |
| Peptide Disruptors | Oncology-focused Biotechs | Metastatic Solid Tumors (EMT-driven) | Interaction assays (need high-purity pDDX5 phosphomimetic proteins). |
| RNA Therapeutics | Emerging Startups | Viral Infections / Oncology | Knockdown validation (need siRNA sets). |
Molecular Differentiation & Assay Strategy
To develop best-in-class DDX5/pDDX5 drugs, molecular differentiation must meet stringent criteria:
-
High subfamily selectivity (avoid DDX17 off-target toxicity): DDX5 and DDX17 share >90% sequence identity in the helicase core domain. Counter-screening with DDX17 recombinant protein using SPR or MST is essential. TarMart provides high-purity DDX5 and DDX17 proteins.
-
Specific binding to pathological pDDX5 (Tyr593): Use phosphomimetic mutant (Y593D) and non-phosphorylatable control (Y593F) to screen for compounds that preferentially bind the phosphorylated state. TarMart offers both variants with >95% purity.
-
Efficient intracellular degradation (for PROTACs): Stable cell lines expressing DDX5 WT or Y593D (generated via TarMart lentivirus) enable reliable DC50 / Dmax measurements by Western blot or high-content screening.